V. Dalm

发表

Prevalence of interferon type I signature in CD14 monocytes of patients with Sjögren's syndrome and association with disease activity and BAFF gene expression

H. Drexhage, W. Beumer, M. Versnel, 2012, Annals of the rheumatic diseases.

MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjögren's syndrome

H. Drexhage, M. Versnel, J. P. Van de Merwe, 2013, Annals of the rheumatic diseases.

Everything you need to know about distal renal tubular acidosis in autoimmune disease

R. Zietse, E. Hoorn, V. Dalm, 2014, Rheumatology International.

Sensitivity and specificity of serum soluble interleukin-2 receptor for diagnosing sarcoidosis in a population of patients suspected of sarcoidosis

J. Miedema, W. Dik, V. Dalm, 2019, PloS one.

T-helper 17 cell cytokines and interferon type I: partners in crime in systemic lupus erythematosus?

O. Corneth, M. Versnel, V. Dalm, 2014, Arthritis Research & Therapy.

Bone Mineral Density in Sjögren Syndrome Patients with and Without Distal Renal Tubular Acidosis

C. V. van Duijn, M. Versnel, V. Dalm, 2016, Calcified Tissue International.

Prevalence of distal renal tubular acidosis in primary Sjögren's syndrome.

R. Zietse, E. Hoorn, M. Versnel, 2015, Rheumatology.

The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis

M. Vonk, W. B. van den Berg, T. Radstake, 2015, Annals of the rheumatic diseases.

TBK1: A key regulator and potential treatment target for interferon positive Sjögren's syndrome, systemic lupus erythematosus and systemic sclerosis.

S. Kamphuis, M. Versnel, V. Dalm, 2018, Journal of autoimmunity.